HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS - Free Report) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $57.00 price target on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals' Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.95 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.84 EPS.
Other analysts also recently issued research reports about the stock. Bank of America reduced their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Citigroup dropped their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, January 29th. Finally, Scotiabank cut their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating for the company in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.53.
Check Out Our Latest Research Report on Apellis Pharmaceuticals
Apellis Pharmaceuticals Trading Down 2.6 %
Shares of NASDAQ:APLS traded down $0.68 during midday trading on Monday, reaching $25.32. 1,186,955 shares of the company's stock were exchanged, compared to its average volume of 1,921,061. The firm's 50 day simple moving average is $29.38 and its two-hundred day simple moving average is $31.26. Apellis Pharmaceuticals has a fifty-two week low of $23.77 and a fifty-two week high of $64.33. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -12.47 and a beta of 0.93.
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same period in the prior year, the business posted ($0.73) EPS. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.
Insider Transactions at Apellis Pharmaceuticals
In related news, CFO Timothy Eugene Sullivan sold 2,170 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the sale, the chief financial officer now owns 88,100 shares of the company's stock, valued at $2,528,470. This represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Caroline Baumal sold 2,816 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the sale, the insider now owns 55,560 shares of the company's stock, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by insiders.
Institutional Trading of Apellis Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the company. Braidwell LP lifted its position in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company's stock worth $90,130,000 after purchasing an additional 2,513,383 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Apellis Pharmaceuticals during the 4th quarter worth approximately $45,504,000. National Bank of Canada FI boosted its position in Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock valued at $44,214,000 after buying an additional 1,385,080 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Apellis Pharmaceuticals by 969.6% in the fourth quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock valued at $48,465,000 after acquiring an additional 1,376,832 shares during the last quarter. Finally, Cibc World Markets Corp acquired a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth approximately $41,014,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.
About Apellis Pharmaceuticals
(
Get Free Report)
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Stories
Before you consider Apellis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.
While Apellis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
